

Att: Henning Gädeke, Chair of the EDCTP Association Board and the Global Health EDCTP3

C/O Dr. Michael Makanga, Executive Director of the Global Health EDCTP3 Joint Undertaking Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

N/Ref. CISM/0724/05/2025

Manhiça, 20th August 2025

Letter of Endorsement for the proposal “Strengthening Institutional Networks and Building Capacity for Epidemiological preparedness in Africa (SINCEP-AFRICA)”

Dear Sir/Madam,

On behalf of FUNDACAO MANHICA (CISM), PIC 954910390, established on RUA 12 BAIRRO CAMBEVE DISTRITO DA MANHICA, VILA DA MANHICA MAPUTO 1929, Mozambique, and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

The Manhica Health Research Centre (CISM), established in 1996, is one of Africa's leading research institutions, with strong laboratory capacity, a clinical trials unit, and an advanced data centre. Over the past 5 years, CISM has emerged as a regional leader in malaria genomics, generating key evidence on parasite diversity, transmission, and drug resistance.

Within the framework of this project, CISM will play a central role in strengthening epidemic preparedness in the SEPA network by leveraging its long-standing experience in population surveillance, clinical trials, and laboratory research. Building on its established expertise in malaria genomics and demographic health surveillance, CISM will focus in this key areas:

- **Infrastructure expansion:** Acquisition of additional sequencing platforms and high-performance computing resources for advanced bioinformatics.
- **Comprehensive training:** Implementation of a train-the-trainer model to ensure sustainability, covering wet-lab techniques, sequencing workflows, and advanced bioinformatics. The training package will include Masters and PhD courses for our young researchers and will be able to host researchers from other sites.
- **Development of SOPs:** Standardization of multi-pathogen workflows, quality control procedures, and rapid reporting pipelines.
- **Integration with surveillance systems:** Embedding genomic data into national and regional platforms to enable real-time outbreak detection and AMR monitoring.
- **Research and Health Response:** Clinical trials to evaluate the safety, efficacy, and cost-

effectiveness of new interventions (drugs, diagnostics, vaccines, and vector-control tools) as well as the Generation of locally relevant evidence to guide clinical care and public health interventions.

CISM will provide its research infrastructure, platforms and personnel to leverage the efforts of the Network in the development of a regional pandemic-ready network of clinical trial sites with surge capacity to rapidly initiate multisite trials during outbreaks.


CISM will contribute to project areas including multi-pathogen genomic surveillance, clinical trials, and epidemic response; will co-lead specific work packages on high quality research implementation, especially on clinical trials, laboratory capacity building, especially on genomic surveillance, health and demographic surveillance and training.

We estimate the total value of this in kind contribution to be EUR 750,000 over a period of 5 years of the grant. This contribution will be through the payment of salaries and benefits for some members of staff not paid by the project, use and maintenance of laboratory equipment, access to data sets, data analysis and management, use and maintenance of clinical facilities as well as use of office space.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programs and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorized by Global Health EDCTP3 JU. Internal dissemination of information within our organization will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours sincerely



**fundação
manhica**
moçambique

Dr. Francisco Saute
Director General